Product image of Jansitin Duo (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Jansitin Duo

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Jansitin Duo (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride, the active ingredient in Jansitin Duo, is a biguanide/DPP-4 inhibitor presented as an oral dosage form for oral use. It treats type 2 diabetes mellitus in adults and combines metformin, which lowers hepatic glucose output, with sitagliptin, a DPP‑4 inhibitor that enhances incretin activity, providing complementary glucose control.

GNH India supplies Jansitin Duo as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

G.L. Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Jansitin Duo, a fixed‑dose combination of metformin and sitagliptin, is used in the management of type 2 diabetes mellitus, targeting multiple pathways to improve overall glucose regulation.

  • Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels.
  • Adjunct to diet and exercise: enhances glycemic control when lifestyle measures alone are inadequate.
  • When metformin monotherapy is insufficient: adds DPP‑4 inhibition to achieve target HbA1c.

How It Works

  • Metformin reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity, while sitagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), leading to increased levels of endogenous incretins (GLP‑1 and GIP). The elevated incretins stimulate glucose‑dependent insulin secretion and suppress glucagon release, together providing better overall blood‑glucose control.

Side Effects

Jansitin Duo may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

  • Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
  • Headache: mild to moderate intensity.
  • Hypoglycemia: especially when combined with insulin or sulfonylureas.
  • Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects

  • Lactic acidosis: a rare but life‑threatening metabolic complication.
  • Pancreatitis: inflammation of the pancreas presenting with severe abdominal pain.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Hepatic dysfunction: elevated liver enzymes or hepatitis.

Precautions & Warnings

Before prescribing Jansitin Duo, clinicians should consider several safety aspects.

  • Renal function assessment: evaluate eGFR and avoid use in severe renal impairment.
  • Lactic acidosis risk: contraindicated in patients with significant hepatic or renal disease.
  • Hypoglycemia monitoring: adjust doses of concomitant insulin or sulfonylureas.
  • Pregnancy and lactation: use only if potential benefits outweigh risks.
  • Drug interactions: review concomitant medications that may affect renal clearance or increase metformin levels.
  • Store at ambient temperature: keep in the original container, protect from moisture and heat.

Avoid Interactions

Jansitin Duo can interact with several medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid)

  • Severe renal impairment: may precipitate metformin accumulation and lactic acidosis.
  • Strong CYP2C8 inhibitors: increase metformin plasma concentrations.
  • Co‑administration with insulin secretagogues: heightened risk of hypoglycemia.

Moderate Interactions (Monitor Closely)

  • Cimetidine: may raise metformin levels.
  • Diuretics: can affect renal clearance of metformin.
  • ACE inhibitors or ARBs: may increase risk of lactic acidosis in susceptible patients.

Frequently Asked Questions

Jansitin Duo is a fixed‑dose oral combination of metformin hydrochloride and sitagliptin indicated for the treatment of type 2 diabetes mellitus in adults. It helps lower both fasting and post‑prandial blood glucose levels when diet, exercise, and monotherapy are insufficient.

Metformin Hydrochloride reduces hepatic glucose production and improves peripheral insulin sensitivity. By decreasing gluconeogenesis and enhancing the uptake of glucose into muscle cells, it contributes to lower blood‑sugar concentrations without stimulating insulin release.

The dose of Jansitin Duo is individualized by the prescribing clinician based on the patient’s glycemic targets, renal function, and concomitant therapies. The prescriber determines the appropriate strength and dosing schedule for each patient.

Safety in pregnancy and lactation has not been fully established. The product should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Jansitin Duo product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with metformin alone, Jansitin Duo adds sitagliptin’s DPP‑4 inhibition, offering a dual mechanism that can achieve better glycemic control without the need for multiple separate tablets. It is generally considered an alternative to other combination therapies such as metformin with sulfonylureas or GLP‑1 receptor agonists.

Jansitin Duo should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency.

Jansitin Duo is taken orally, usually once daily with a meal to reduce gastrointestinal discomfort. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

The most serious risks include lactic acidosis, a rare but potentially fatal condition, and pancreatitis. Patients should be monitored for signs of severe abdominal pain, unexplained nausea, or rapid breathing, and the medication should be stopped immediately if such symptoms occur.

Jansitin Duo is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, and those with a history of lactic acidosis. It should also be used with caution in individuals with significant hepatic disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT